Piper Jaffray downgrades TomoTherapy (NASDAQ: TOMO) from Buy to Neutral and lowers their price target from $14 to $7. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE